416 related articles for article (PubMed ID: 33130903)
1. Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
Vitanza NA; Biery MC; Myers C; Ferguson E; Zheng Y; Girard EJ; Przystal JM; Park G; Noll A; Pakiam F; Winter CA; Morris SM; Sarthy J; Cole BL; Leary SES; Crane C; Lieberman NAP; Mueller S; Nazarian J; Gottardo R; Brusniak MY; Mhyre AJ; Olson JM
Neuro Oncol; 2021 Mar; 23(3):376-386. PubMed ID: 33130903
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma.
Noll A; Myers C; Biery MC; Meechan M; Tahiri S; Rajendran A; Berens ME; Paine D; Byron S; Zhang J; Winter C; Pakiam F; Leary SES; Cole BL; Jackson ER; Dun MD; Foster JB; Evans MK; Pattwell SS; Olson JM; Vitanza NA
Neoplasia; 2023 Sep; 43():100921. PubMed ID: 37603953
[TBL] [Abstract][Full Text] [Related]
3. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
[TBL] [Abstract][Full Text] [Related]
4. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas.
Lu VM; Daniels DJ
Adv Exp Med Biol; 2021; 1283():73-84. PubMed ID: 33155139
[TBL] [Abstract][Full Text] [Related]
6. HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53.
Capdevielle C; Desplat A; Charpentier J; Sagliocco F; Thiebaud P; Thézé N; Fédou S; Hooks KB; Silvestri R; Guyonnet-Duperat V; Petrel M; Raymond AA; Dupuy JW; Grosset CF; Hagedorn M
Neuro Oncol; 2020 Apr; 22(4):550-562. PubMed ID: 31711240
[TBL] [Abstract][Full Text] [Related]
7. Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models.
Hennika T; Hu G; Olaciregui NG; Barton KL; Ehteda A; Chitranjan A; Chang C; Gifford AJ; Tsoli M; Ziegler DS; Carcaboso AM; Becher OJ
PLoS One; 2017; 12(1):e0169485. PubMed ID: 28052119
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening.
Lin GL; Wilson KM; Ceribelli M; Stanton BZ; Woo PJ; Kreimer S; Qin EY; Zhang X; Lennon J; Nagaraja S; Morris PJ; Quezada M; Gillespie SM; Duveau DY; Michalowski AM; Shinn P; Guha R; Ferrer M; Klumpp-Thomas C; Michael S; McKnight C; Minhas P; Itkin Z; Raabe EH; Chen L; Ghanem R; Geraghty AC; Ni L; Andreasson KI; Vitanza NA; Warren KE; Thomas CJ; Monje M
Sci Transl Med; 2019 Nov; 11(519):. PubMed ID: 31748226
[TBL] [Abstract][Full Text] [Related]
9. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
[TBL] [Abstract][Full Text] [Related]
10. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
[TBL] [Abstract][Full Text] [Related]
11. [Diffuse midline glioma].
Saito R
No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047).
Monje M; Cooney T; Glod J; Huang J; Peer CJ; Faury D; Baxter P; Kramer K; Lenzen A; Robison NJ; Kilburn L; Vinitsky A; Figg WD; Jabado N; Fouladi M; Fangusaro J; Onar-Thomas A; Dunkel IJ; Warren KE
Neuro Oncol; 2023 Dec; 25(12):2262-2272. PubMed ID: 37526549
[TBL] [Abstract][Full Text] [Related]
13. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
Dono A; Takayasu T; Ballester LY; Esquenazi Y
J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
[TBL] [Abstract][Full Text] [Related]
14. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.
Khuong-Quang DA; Buczkowicz P; Rakopoulos P; Liu XY; Fontebasso AM; Bouffet E; Bartels U; Albrecht S; Schwartzentruber J; Letourneau L; Bourgey M; Bourque G; Montpetit A; Bourret G; Lepage P; Fleming A; Lichter P; Kool M; von Deimling A; Sturm D; Korshunov A; Faury D; Jones DT; Majewski J; Pfister SM; Jabado N; Hawkins C
Acta Neuropathol; 2012 Sep; 124(3):439-47. PubMed ID: 22661320
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.
Bailey CP; Figueroa M; Gangadharan A; Yang Y; Romero MM; Kennis BA; Yadavilli S; Henry V; Collier T; Monje M; Lee DA; Wang L; Nazarian J; Gopalakrishnan V; Zaky W; Becher OJ; Chandra J
Neuro Oncol; 2020 Sep; 22(9):1302-1314. PubMed ID: 32166329
[TBL] [Abstract][Full Text] [Related]
16. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
Castel D; Philippe C; Calmon R; Le Dret L; Truffaux N; Boddaert N; Pagès M; Taylor KR; Saulnier P; Lacroix L; Mackay A; Jones C; Sainte-Rose C; Blauwblomme T; Andreiuolo F; Puget S; Grill J; Varlet P; Debily MA
Acta Neuropathol; 2015 Dec; 130(6):815-27. PubMed ID: 26399631
[TBL] [Abstract][Full Text] [Related]
17. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
[TBL] [Abstract][Full Text] [Related]
18. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
[TBL] [Abstract][Full Text] [Related]
19. Slow-Growing Thalamic Glioma with Histone H3 Lysine 27-to-Methionine Mutation: 3-Year Follow-Up Before Surgical Intervention.
Chanchotisatien A; Pan J; Du Z; Qiu T; Yu J; Chu S
World Neurosurg; 2019 Jul; 127():266-268. PubMed ID: 30981797
[TBL] [Abstract][Full Text] [Related]
20. Global activation of oncogenic pathways underlies therapy resistance in diffuse midline glioma.
Georgescu MM; Islam MZ; Li Y; Circu ML; Traylor J; Notarianni CM; Kline CN; Burns DK
Acta Neuropathol Commun; 2020 Jul; 8(1):111. PubMed ID: 32680567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
